Thomas Jefferson University

Jefferson Digital Commons
Kimmel Cancer Center Papers, Presentations,
and Grand Rounds

Kimmel Cancer Center

7-22-2018

Role of HOX Genes in Stem Cell Differentiation and Cancer.
Seema Bhatlekar
Helen F. Graham Cancer Center and Research Institute; University of Delaware

Jeremy Z Fields
CATX Inc.

Bruce M. Boman
Thomas Jefferson University; Helen F. Graham Cancer Center and Research Institute; University of
Delaware; CATX Inc.

Follow this and additional works at: https://jdc.jefferson.edu/kimmelgrandrounds
Part of the Oncology Commons

Let us know how access to this document benefits you
Recommended Citation
Bhatlekar, Seema; Fields, Jeremy Z; and Boman, Bruce M., "Role of HOX Genes in Stem Cell
Differentiation and Cancer." (2018). Kimmel Cancer Center Papers, Presentations, and Grand
Rounds. Paper 62.
https://jdc.jefferson.edu/kimmelgrandrounds/62
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Kimmel Cancer Center Papers, Presentations, and Grand Rounds by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Hindawi
Stem Cells International
Volume 2018, Article ID 3569493, 15 pages
https://doi.org/10.1155/2018/3569493

Review Article
Role of HOX Genes in Stem Cell Differentiation and Cancer
Seema Bhatlekar ,1,2 Jeremy Z. Fields,3 and Bruce M. Boman

1,2,3,4

1

Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute, Newark, DE, USA
Department of Biological Sciences, University of Delaware, Newark, DE, USA
3
CATX Inc., Princeton, NJ, USA
4
Kimmel Cancer Center, Thomas Jeﬀerson University, Philadelphia, PA, USA
2

Correspondence should be addressed to Bruce M. Boman; brucemboman@gmail.com
Received 1 March 2018; Revised 8 May 2018; Accepted 15 May 2018; Published 22 July 2018
Academic Editor: Jing Huang
Copyright © 2018 Seema Bhatlekar et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
HOX genes encode an evolutionarily conserved set of transcription factors that control how the phenotype of an organism becomes
organized during development based on its genetic makeup. For example, in bilaterian-type animals, HOX genes are organized in
gene clusters that encode anatomic segment identity, that is, whether the embryo will form with bilateral symmetry with a head
(anterior), tail (posterior), back (dorsal), and belly (ventral). Although HOX genes are known to regulate stem cell (SC)
diﬀerentiation and HOX genes are dysregulated in cancer, the mechanisms by which dysregulation of HOX genes in SCs causes
cancer development is not fully understood. Therefore, the purpose of this manuscript was (i) to review the role of HOX genes
in SC diﬀerentiation, particularly in embryonic, adult tissue-speciﬁc, and induced pluripotent SC, and (ii) to investigate how
dysregulated HOX genes in SCs are responsible for the development of colorectal cancer (CRC) and acute myeloid leukemia
(AML). We analyzed HOX gene expression in CRC and AML using information from The Cancer Genome Atlas study. Finally,
we reviewed the literature on HOX genes and related therapeutics that might help us understand ways to develop SC-speciﬁc
therapies that target aberrant HOX gene expression that contributes to cancer development.

1. HOX Genes
HOX genes are master transcriptional regulators that have
diverse roles from embryogenesis to carcinogenesis. The
HOX genes are an evolutionary conserved family of genes
that control anterior-posterior axis and dorsal-ventral
anatomic development during embryogenesis. In humans
there are a total of 39 HOX genes situated in clusters on four
diﬀerent chromosomes (7p15, 17q21.2, 12q13, and 2q31).
These clusters are named as four HOX families: HOXA,
HOXB, HOXC, and HOXD. Each family consists of 13 paralog groups with nine to eleven numbers assigned based on
their sequence similarity and position within the cluster
(Figure 1(a)). HOX genes contain two exons and a single
intron. Exon 2 contains a 120-nucleotide sequence, known
as homeobox. This homeobox encodes a 61 amino acid helixturn-helix motif known as a homeodomain (Figure 1(b)).

The protein products of the HOX genes are transcription
factors that are capable of binding to speciﬁc nucleotide
sequences on the DNA.
1.1. HOX Genes and Stem Cell Diﬀerentiation. SCs are multipotent cells that have the ability to self-renew or to diﬀerentiate along multiple lineages. HOX genes have been shown to
play crucial roles during SC diﬀerentiation from embryonic
stages of development to tissue-speciﬁc SC functions. Of
the 39 HOX genes, mutations in 10 HOX genes (HOXA1,
HOXA2, HOXA11, HOXA13, HOXB1, HOXB13, HOXC13,
HOXD4, HOXD10, and HOXD13) have been found to cause
human disorders with variations in their inheritance patterns, penetrance, expressivity, and mechanisms of pathogenesis [1]. Congenital defects caused by mutations in
HOX genes support the concept that HOX gene function is
crucial for SCs during development and diﬀerentiation.
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Figure 1: HOX genes and genome organization. (a) In humans, there are a total of 39, clustered into four families, namely, HOXA, HOXB,
HOXC, and HOXD. Each family consists of 13 paralogous groups with nine to eleven numbers assigned based on their sequence similarity
and position within the cluster. (b) HOX genes have two exons and 1 intron. Exon 2 has a 120-nucleotide sequence, called a Homeobox that
encodes a 61 amino acid HOX protein.

Therefore, we reviewed the published literature for the role
of HOX genes during diﬀerentiation of three main types of
SC, namely, (i) embryonic SCs, (ii) adult SCs (hematopoietic
SCs, colonic SCs, and mesenchymal SCs), and (iii) induced
pluripotent SCs.

ESC diﬀerentiation into HSCs by directly targeting multiple
essential hematopoietic transcription factors and epigenetic
factors [20]. Overall, these results show that complex regulatory mechanisms exist through which Hox genes are
expressed in ESCs and function during diﬀerentiation.

1.1.1. HOX Genes and Embryonic Stem Cell Diﬀerentiation.
Embryonic stem cells (ESCs) are obtained from the inner cell
mass of the blastocyst. ESCs are pluripotent cells that can give
rise to most cell types except the placenta and umbilical cord.
Retinoic acid (RA) signaling regulates HOX gene expression
in ESCs during embryonic development. In adult neurogenesis, ESCs treated with RA almost exclusively diﬀerentiate
into neurons and develop a HOX-related expression proﬁle
[2]. Retinoic acid response elements (RAREs) are found in
regulatory regions of many HOX genes [3, 4]. In mice,
RAREs are found in Hoxa1, Hoxa4, Hoxb1, Hoxb4, and
Hoxd4 [5–14]. Several HOX genes have been found to be
strongly upregulated during diﬀerentiation in the presence
of RA [15]. RA receptor γ (RARγ) was found to be essential
for RA-induced HOX gene transcriptional activation in
ESCs. Deletion of its binding site in the Hoxa1 enhancer
attenuates transcriptional and epigenomic activation of both
Hoxa and Hoxb gene clusters. It was reported that RA/RARγ
signaling is critical for the removal of histone methylation
occurring on the amino terminal tail core of the core histone
H3 (H3K27me3) from activated Hox genes during ESC differentiation [16]. The entire Hox cluster is actively repressed
in ESCs by polycomb repressor complexes and plays key
regulatory roles during their diﬀerentiation to multipotent
progenitors in developing tissues [17]. As ESCs diﬀerentiate
into diﬀerent lineages, Hox gene clusters become activated
in a controlled and sequence-speciﬁc manner [17, 18]. It
has been shown that timely induction of Hoxb1 in ESCs
results in the diﬀerentiation of neuronal SCs and neural progenitors of distinct posterior identities [19]. It is well-known
that Hoxb4 overexpression in ESCs confers long-term repopulating ability to ESC-derived hematopoietic stem cells
(HSCs). Furthermore, Hoxb4 acts as a master regulator of

1.1.2. HOX Genes and Adult Stem Cells. Adult SCs, also
referred to as somatic or tissue-speciﬁc SCs, give rise to
diﬀerent cell types that are speciﬁc to each tissue type or
organ in which they reside. HOX genes are crucial for
the maintenance and functioning of adult SCs. Here, we
focus on three types of adult SCs: hematopoietic SCs that
generate entire blood cell lineages, colonic SCs that reside
at the base of the normal crypt and are responsible for
colonic tissue renewal and proper functioning of the colon,
and mesenchymal SCs isolated from the stroma and that
generate various diﬀerentiated cell types from bone, cartilage, and fat cells.
(1) HOX Genes and Hematopoietic Stem Cells. Hematopoietic
stem cells (HSCs) are generally found in the bone marrow
but can also be isolated from the peripheral blood, umbilical
cord blood, and fetal liver. HOX genes are expressed in HSCs
and progenitors in a lineage-speciﬁc and diﬀerentiation
stage-restricted manner. For example, HOXB3, HOXB4,
and HOXA9 are abundantly expressed in HSCs, whereas
HOXB8 and HOXA10 are expressed only in myeloid committed cells. Recent studies showed that HOXA family genes
are mostly expressed in the myeloid cells, HOXB family
genes are mostly expressed in the erythroid cells, and HOXC
family genes are commonly seen in the lymphoid cells.
HOXD family genes are not expressed during hematopoiesis
despite their similarities to other HOX gene clusters [21–24].
Since speciﬁc HOX genes are essential for SC diﬀerentiation
into speciﬁc blood cell types, we present a diagram of all
known HOX genes associated with hematopoiesis (Figure 2).
1.1.3. HOXA5. HOXA5 overexpression in bone marrow
CD34+ SCs and cord blood CD34+ CD38− cells resulted in
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Figure 2: HOX gene expression during hematopoiesis. The hematopoietic stem cell (HSC) is a multipotent stem cell that has the ability to
give rise to common lymphoid progenitor (CLP) and common myeloid progenitor (CMP) cells. HOXA9, HOXB4, and HOXB6 are known
to be expressed in HSC and regulate HSC self-renewal. HOXA5 and HOXA9 are involved in the proliferation and diﬀerentiation of HSC
to CMP, and HOXA9 regulates the diﬀerentiation of HSC into CLP. HOXB3 is expressed during the diﬀerentiation of pre-B cells into B
cells. HOXA5 and HOXC8 are expressed during erythroid diﬀerentiation of megakaryocyte-erythrocyte progenitors (MEP) whereas
HOXA7 is expressed during megakaryocyte diﬀerentiation. HOXC3 and HOXC4 are crucial during erythroid lineage diﬀerentiation.
HOXC8 is shown to play a regulatory role during the diﬀerentiation of granulocyte-monocyte progenitor (GMP) cells. HSC:
hematopoietic stem cells; CMP: common myeloid progenitor; CLP: common lymphoid progenitor; MEP: megakaryocyte-erythrocyte
progenitor; GMP: granulocyte-monocyte progenitor; BFU-E: erythroid burst-forming units; CFU-E: erythroid colony-forming unit;
CFU-Meg: megakaryocyte colony-forming unit; CFU-mast: mast colony-forming unit; CFU-Eo: eosinophil colony-forming unit; CFU-GM:
granulocyte-monocyte colony-forming unit; CFU-Oc: osteoclasts colony-forming unit.

a signiﬁcant shift in myeloid diﬀerentiation [25]. When
HOXA5 was overexpressed in HSCs, erythroid progenitors
(burst-forming unit-erythroid BFU-E) were signiﬁcantly
decreased in frequency among all progenitors, with no reduction in total colony-forming unit (CFU) numbers [25]. Similarly, the overexpression of HOXA5 inhibited erythroid
diﬀerentiation of K562 cells [26]. In contrast, the knockdown
of HOXA5 in human bone marrow cells resulted in the
inhibition of granulocytic/monocytic hematopoiesis and
increased erythroid progenitors [26]. Overall, these studies
showed that HOXA5 is crucial for the balance between myeloid and erythroid diﬀerentiation.
1.1.4. HOXA7. Hoxa7 knockout mice showed reduced megakaryocytic/erythroid progenitors (MEP) and exhibited reticulocytosis and thrombocytopenia without anemia [27],
suggesting that HOXA7 is required for MEP diﬀerentiation.

1.1.5. HOXA9. HOXA9 is one of the most abundant HOX
genes in HSCs. HOXA9 is downregulated during HSC diﬀerentiation [24, 28]. Hoxa9 knockout mice displayed marked
lymphopenia (low levels of lymphocytes in the blood) and
substantial reductions of common lymphoid progenitors
(CLPs) and lymphoid precursors. In addition, signiﬁcant
reduction of common myeloid progenitors (CMPs) and
granulocyte/monocyte progenitors (GMPs) was observed
upon Hoxa9 knockout in vivo [27]. Hoxa9 knockout mice
also showed a reduction in the number of total leukocytes
[29], and the loss of expression of Hoxa9 impaired the proliferating and repopulating ability of HSCs [30]. HOXA9 thus
appears to regulate HSC proliferation, self-renewal, and myeloid and lymphoid diﬀerentiation.
1.1.6. HOXA10. HOXA10 overexpression in human cord
blood and fetal liver CD34+ cells resulted in a signiﬁcant

4

Stem Cells International

production of blast cells (undiﬀerentiated blood cells, commonly seen in acute leukemia) and myelopoiesis concomitant with a complete block of erythroid diﬀerentiation and
a severe reduction in B cell development [31]. Thus, these
ﬁndings suggest that the regulation of HOXA10 expression
is crucial for preventing abnormal development and diﬀerentiation of HSCs.

1.1.12. HOXC8. A signiﬁcant reduction in the number of erythroid burst-forming units (BFU-E) and in CFU-GM
occurred in Hoxc8 null mice, although the peripheral blood
cell counts were normal [45] suggesting that HOXC8 plays
a role during MEP (megakaryocyte-erythroid progenitor)
diﬀerentiation into BFU-E and GMP diﬀerentiation into
CFU-GM.

1.1.7. HOXB3. In mice, the overexpression of Hoxb3 blocked
B and T cell diﬀerentiation and caused a delay in myeloid
precursor proliferation [32], whereas the knockout of Hoxb3
in mice at 6 months of age caused signiﬁcant impairment of B
cell development in the bone marrow [33].

(1) HOX Genes and Colonic Stem Cells. We previously
showed that normal colonic SCs are found at the base of
the normal human colon crypt and can be isolated using
SC markers such as aldehyde dehydrogenase (ALDH1),
ALCAM (CD166), and LGR5 [46–48]. The overpopulation
of colonic SCs drives colorectal cancer (CRC) development
[47, 48]. We studied the expression of HOX genes in normal
colonic SCs by microarray proﬁling. Our analysis showed
that HOXA4, HOXA9, and HOXD10 are expressed more in
colonic SCs than in proliferating cells or diﬀerentiating crypt
cells [49]. Further studies showed that HOXA4 and HOXA9
are enriched in SCs during CRC development and that the
dysregulation of HOXA4 and HOXA9 expression promotes
self-renewal and proliferation of colonic SCs [50]
(Figure 3). The siRNA knockdown of HOXA4 and HOXA9
in colon cancer cell lines SW480 and HT29 reduced proliferation and sphere-forming ability of colon SCs [50] thus suggesting regulatory roles of HOX genes during colon SC
maintenance and diﬀerentiation.

1.1.8. HOXB4. HOXB4 is known to enhance primitive hematopoietic cell growth by increasing self-renewal without
aﬀecting homeostatic control of HSC population size or of
the rate of HSC production. The retention of full lymphomyeloid repopulating potential and enhanced in vivo regenerative potential demonstrates the feasibility of achieving
signiﬁcant ex vivo expansion of HSCs without functional
impairment [34–39]. Hoxb3 and Hoxb4 double-knockout
mice showed defects in endogenous hematopoiesis with
reduced cellularity of HSC regeneration. Hoxb3−/Hoxb4−
mice showed reduction in hematopoietic progenitor numbers without perturbing lineage commitment [40].
1.1.9. HOXB6. Hoxb6 overexpression in mice resulted in
HSC and myeloid progenitor cell expansion but inhibited
erythropoiesis and lymphopoiesis [41]. Upregulation of
HOXB6 is often seen in acute myeloid leukemia (AML).
Cytogenetic analysis of a subset of HOXB6-induced AMLs
revealed recurrent deletions of chromosome band 2D-E4, a
region frequently deleted in HOXA9-induced AMLs. The
biologic eﬀects of HOXB6 were seen to be largely dependent
on DNA binding but they were independent of direct interaction of PBX1 [41]. The knockout of Hoxb6 resulted in an
increase in early erythroid progenitors in murine bone marrow and fetal liver cells [42]. Thus, HOXB6 is critical not only
for HSC self-renewal and maintenance but also for regulatory
balance between lymphoid and myeloid diﬀerentiation.
1.1.10. HOXC3. An antisense oligonucleotide against Hoxc3
inhibited the formation of colony-forming units (CFUs) of
erythroid-derived colonies without any changes in size or
degree of hemoglobinization. Early erythroid burst-forming
unit colonies or myeloid colonies were not aﬀected,
demonstrating that Hoxc3 is involved in an early step in
proliferation of the erythroid colony-forming unit subset of
progenitor cells [43].
1.1.11. HOXC4. The enforced expression of HOXC4 in
human CD34+ cells induced a signiﬁcant increase in the
number of erythroid colonies compared with granulocyte/
macrophage colony-forming units (CFU-GM), without perturbing, at least in vitro, the maturation program of these
cells. On the other hand, HOXC4 overexpression did not
induce any skewing in the colony types derived from the
myeloid lineage [44].

(2) HOX Genes and Mesenchymal Stem Cells. Mesenchymal
stem cells (MSCs) isolated from the umbilical cord blood
express HOXA9, HOXB7, HOXC10, and HOXD6, whereas
bone marrow-derived MSCs express HOXB7 and HOXD6
[51]. HOXC10 was found to be diﬀerentially expressed in
amnion- and decidua-derived MSCs [51]. HOX genes, particularly HOXA9, HOXB7, HOXC10, and HOXD8, were used
as biomarkers to distinguish between MSCs derived from
unrestricted somatic stem cells and cord blood [51]. A study
by Woo et al. [52] showed that the expression of HOXC13
increased whereas HOXD13 expression decreased as bone
marrow-derived MSCs diﬀerentiated into osteoblasts during
osteogenesis. Taken together, these ﬁndings indicate that distinct expression patterns of HOXA5, HOXA10, HOXB6,
HOXB7, HOXC4, HOXC6, HOXC8, HOXC9, HOXC10,
HOXD3, and HOXD8 exist in MSCs derived from diﬀerent
human sources [52]. Hoxb2, Hoxb5, Hoxb7, and Hoxc4 genes
were found to regulate self-renewal and diﬀerentiation of
murine MSCs [53].
HOX genes have been shown to play critical roles during
osteogenesis of human MSCs. Histone demethylase KDM6B
controlled HOX expression by removing histone 3K27 trimethylation (H3K27me3) and reduced KDM6B signiﬁcantly
by reducing osteogenic diﬀerentiation and increasing adipogenic diﬀerentiation [54]. The role of HOX genes during
diﬀerentiation of human vascular wall-resident CD44+
multipotent stem cells (VW-MPSCs) was also studied [55].
VW-MPSCs are capable of diﬀerentiating into pericytes
and smooth muscle cells. This study demonstrated that the
expression of HOXB7, HOXC6, and HOXC8 is diﬀerentially
expressed in VW-MPSCs as compared to terminally
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Figure 3: HOX gene expression during colonocyte diﬀerentiation. Normal colonic crypts consist of mainly three types of cells based on their
location in the crypt. Colon stem cells (SCs) reside at the base of the colonic crypt (shown in blue color). HOXA4, HOXA9, and HOXD10 are
expressed in colonic SCs and regulate colonic crypt SC diﬀerentiation [49, 50]. SCs generate transit-amplifying cells (shown in green color)
that are actively proliferating and diﬀerentiating (shown in gold-bronze yellow color) as they move up the axis in the colonic crypt. Finally,
fully diﬀerentiated or terminally diﬀerentiating cells are found at the top of the crypt (shown in brown color). Studies have shown that HOXA
family genes are expressed mostly in proliferating colonic cells, and HOXC family genes are expressed in diﬀerentiating cells [68]. HOXB and
HOXD family genes are expressed throughout the colonic crypts [68]. In colon tumors, the dysregulation of HOXA4 and HOXA9 in colon
SCs caused aberrant self-renewal and proliferation, contributing to colon carcinoma [50]. HOXC8 and HOXC9 are expressed in the
diﬀerentiating cells in the colonic crypt [68].

diﬀerentiated human aortic smooth muscle cells, endothelial
cells, and undiﬀerentiated pluripotent ESCs. The knockdown
of HOX genes in VW-MPSCs reduced their sprouting capacity and increased their levels of smooth muscle markers,
transgelin and calponin, as well as histone H1. In addition,
changes in methylation patterns of the TAGLN promoter
were observed [55]. Overall, this study suggested a role for
HOX genes in regulating diﬀerentiation of human VWMPSC into smooth muscle cells via epigenetic mechanisms.
The results of this study will help us understand VWMPSC-dependent vascular disease processes such as neointima formation and tumor vascularization [55].
1.1.13. HOX Genes and Induced Pluripotent Stem Cells.
Induced pluripotent stem cells (iPSCs) are cells that are
engineered in the lab by converting tissue-speciﬁc adult
SCs into cells that possess ESC-like properties. iPSCs, like
ESCs, did not express HOX genes [56]. Although suppression of HOX gene expression was observed in iPSCs, transient WNT/β-catenin signaling triggered the activation of
the CDX/HOX pathway, which in turn conferred a hematogenic posterior mesoderm phenotype to diﬀerentiating
human iPSCs [57].

2. HOX Genes and Cancer
In recent years, it has been shown that HOX genes are not
only responsible for proper embryonic development but they
are also associated with cancer development [58]. In the next
section of this review, we focus on the role of HOX genes in
cancer development, particularly colorectal cancer (CRC)
and acute myeloid leukemia (AML).

2.1. HOX Genes in CRC. Aberrant expression of HOX genes
is seen in CRC [49, 50, 58, 59]. We previously reported that
HOXA4, HOXA9, and HOXD10 are expressed in normal
colonic SCs and dysregulation of HOX genes leads to aberrant SC diﬀerentiation, contributing to CRC development
and growth. Furthermore, we showed that HOXA4 and
HOXA9 genes promote self-renewal and proliferation of
colonic SCs, contributing to CRC development [49, 50].
In this review, we also evaluate the role of HOX genes
during CRC development using The Cancer Genome Atlas
(TCGA) database. Tumor samples were collected from newly
diagnosed patients (i) with colon or rectum adenocarcinoma
(ii) undergoing surgical resection, and (iii) having received
no prior treatment for their disease, including no chemotherapy and no radiotherapy. All cases were collected regardless
of surgical stage or histologic grade. Cases were staged
according to the American Joint Committee on Cancer
(AJCC) staging system. Each frozen tumor specimen had a
companion normal tissue specimen which could be blood/
blood components, adjacent normal tissue taken from
greater than 2 cm from the tumor, or previously extracted
germline DNA from the blood [60]. Our analysis showed that
HOXB9 was the most upregulated gene at all stages
(Figure 4). HOXB6 and HOXB8 expression increased from
stages I to IV but dramatically decreased at stage IVA. Interestingly, the expression of HOXB6 and HOXB8 was increased
during stages I and II and decreased at stage III but again
increased at stage IV (Figure 4(f)).
HOXD family gene expression increased at stage IVA
compared to all other stages of CRC (Figure 4). Our analysis
showed that there is no diﬀerence in HOX gene expression
based on gender (Figure 5). When we compared TCGA datasets for HOX gene expression in CRC to overall survival,
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increased HOXB13 was found to be associated with decreased
survival (data not shown). It was reported earlier that missense germline HOXB13 mutations, most commonly in
G84E (HOXB13 p. Gly84Glu), are associated with earlyonset prostate cancer and possibly associated with breast cancer and colorectal cancer [61–63]. Unlike HOXB13, increased
HOXB8 expression was associated with increased survival.
We observed similar trends in expression of other HOX
genes, whereby changes in the level of expression was correlated with improved survival and greater in tumor than
tumor-free CRC cases (discussed below).
Next, we analyzed HOX expression based on their family
gene clusters. Among all HOX families, the HOXB family
showed the highest expression in CRC. In the HOXB family,
HOXB9, HOXB8, HOXB6, HOXB13, HOXB, and HOXB7
were all overexpressed in CRC (Figure 6(a)). The HOXA
family showed the next highest expression. In the HOXA

family, HOXA9 and HOXA10 showed higher expression
than the remaining HOXA family genes (Figure 6(b)).
Among HOXD family members, HOXD10, HOXD11,
HOXD13, and HOXD9 showed increased expression compared to the others (Figure 6(c)). The HOXC family of genes
showed the least expression compared to HOXA, HOXB,
and HOXD (Figure 6(d)).
We further assessed HOX genes as a function of overall
patient survival. Because we previously found that HOXA4
and HOXD10 are expressed in crypt SCs, we measured
HOXA4 and HOXD10 levels in CRC cases (n = 220) based
on high versus low expression (cutoﬀ at 25th percentile).
HOXA4 and HOXD10 high-expressing cases (n = 110) of
CRC patients showed overall low survival rates. Increased
HOXD10 expression was found to be signiﬁcantly associated
with poor overall survival in CRC (Figure 7(a)). HOXD10
high expressers showed only a 15% survival rate versus 55%
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survival rate of HOXD10 low expressers (Figure 7(a)).
HOXA4 high expressers showed about a 30% survival rate
as compared to a 50% survival rate of HOXA4 low expressers
(Figure 7(b)). We also analyzed the association of HOXA9
with the SC marker ALDH1A1 in CRC patients using TCGA
database. A signiﬁcant positive correlation was observed
between HOXA9 and ALDH1A1 in CRC (r = 0 12, P = 0 048)
(Figure 8(a)). Retinoid receptors, RXRB, showed negative signiﬁcant correlation with ALDH1A1 (r = −0 13, P = 0 026)
(Figure 8(b)). Another stem cell marker, ALCAM (also
known as CD166), was correlated with HOX gene expression in CRC. Expression of HOXA4 negatively correlated
with ALCAM in CRC patients (r = −0 14, P = 0 024)
(Figure 8(c)). HOXA9 was positively correlated with ALCAM
(r = 0 18, P = 0 0027) (Figure 8(d)). HOXD10 showed significant negative correlation with ALCAM (r = −0 18, P = 0 003)
(Figure 8(e)) whereas HOXB8 showed a signiﬁcant positive
correlation with ALCAM (r = 017, P = 0 006) (Figure 8(f)).
Other published reports on the involvement of HOX
genes in CRCs were reviewed [49]. The expression of
HOXD8 is downregulated in clinical CRCs compared to
normal colon tissues, and the stable expression of HOXD8
in CRC cells signiﬁcantly reduced cell proliferation, anchorage independent-growth, and invasion. Apoptotic inhibitor
genes such as STK38 and MYC were found to be negatively
associated with HOXD8 in analyses using The Cancer
Genome Atlas (TCGA). Mansour and Senga demonstrated
the ability of HOXD8 to activate caspases 6 and 7 and cleave
PARP, thus enhancing apoptosis of CRC cells [64]. A study
by Chen et al. showed that HOXD3 is upregulated in human
RKO colon cancer cells. The inhibition of HOXD3 by shRNA
in RKO cells signiﬁcantly decreased proliferation and colony
formation and increased apoptosis of RKO colon cancer cells.
HOXD3-inhibited cells were arrested in the G2 phase of the
cell cycle [65]. Among HOXD clusters, induction of the
expression of HOXD8, HOXD9, HOXD10, or HOXD12
induces growth arrest and neuronal diﬀerentiation with
downregulation of cell cycle-promoting genes and upregulation of diﬀerentiation genes. Other HOXD genes such as
HOXD1, HOXD3, HOXD4, HOXD11, and HOXD13 had no
eﬀects or only partial eﬀects on neuroblastoma cell proliferation or diﬀerentiation [66]. These ﬁndings suggest that
HOXD genes have distinct functions in the induction of cancer cell diﬀerentiation. Other HOX genes, such as HOXB6,
HOXB8, HOXC8, HOXC9, and CDX1 were also found to be
dysregulated in human CRC development [67]. Furthermore, the HOXA family gene was abundantly expressed in
colonic adenocarcinoma cells [68]. Overall, these ﬁndings
suggest that HOX genes play key regulatory roles during
maintenance of normal colon SC diﬀerentiation and that
aberrant expression is associated with CRC development.
2.1.1. CDX1/CDX2 Genes in CRC. Another set of Hox genes,
the Cdx genes (also classiﬁed as ParaHox genes or caudalrelated homeobox genes), is expressed in a wide variety of
organisms [69]. Three Cdx genes, Cdx1, Cdx2, and Cdx4,
exist in mouse and humans (CDX1, CDX2 and CDX4) and
regulate anterior-posterior patterning [70, 71]. The CDX
genes are not located in a homeobox cluster, CDX1 is located
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on human chromosome 5q31–33, CDX2 gene is on chromosome 13q12, and CDX3 is on Xq13.2. In mice, Cdx1 and
Cdx2 are important for gastrointestinal tract development.
CDX1 and CDX2 are also actively expressed in adult intestinal epithelium and are involved in the regulation of enterocyte proliferation and diﬀerentiation as well as WNTmediated beta-catenin signaling [70, 72, 73]. Moreover,
reduced expression of CDX2 appears to contribute to the
development of intestinal neoplasia and is a prognostic biomarker for stage II and stage III colon cancer by identifying
high-risk patients who might beneﬁt from adjuvant chemotherapy [74–76].
2.1.2. HOX Genes in AML. Studies of AML patients show that
many cases (~35%) have mutations in type III receptor tyrosine kinase FLT3 and that HOXB2 and HOXB3 are increased
in AML patients with FTL3-ITD (internal tandem duplication) mutation. The overexpression of Hoxb2 and Hoxb3
in mouse pro-B cells resulted in decreased FLT3-ITDdependent cell proliferation, reduced colony formation, and
increased apoptosis, suggesting that HOXB2 and HOXB3 are
regulators of FLT3-ITD-driven AML [77]. Several studies also
showed that HOX genes promote AML development by forming chimeric fusions with other genes. Fusion of the nucleoprotein NUP98 with HOXA9 via chromosome translocation
t(7;11) (p15s;p15) causes development of AML [78]. Mice
overexpressing Hoxa9 and Meis1a induced growth factordependent AML in less than 3 months. However, the overexpression of Hoxa9, Mesi1a, or Pbx1b alone, or in combination
with Hoxa9 and Pbx1b, failed to transform these cells acutely
within 6 months posttranslation [79]. NUP98-HOXA9 fusion
genes induced long-term proliferation and blocked diﬀerentiation of human CD34+ HSCs [80]. Recent data showed that
mixed lineage leukemia (MLL) is crucial for NUP98-HOXA9
leukemia initiation [81]. We analyzed the TCGA dataset and
did overall survival analysis for HOXA9 in AML patients
(n = 74) and found that HOXA9 high expressers had a 20%
survival rate compared to HOXA9 low expressers which had
a 50% survival rate (Figure 9).
2.2. Cancer Stem Cells. Cancer stem cells (CSCs) are multipotent and have the ability to undergo both self-renewal
and diﬀerentiation. We and others have shown that CSCs
are the root cause of cancer development [46, 47]. These
CSCs are resistant to chemotherapy and radiation. Previously, we identiﬁed HOXA4, HOXA9, and HOXD10 signatures for normal colonic SCs and that these HOX genes
are upregulated during CRC development. Indeed, HOXA4
and HOXA9 were found to have roles in self-renewal and
proliferation of colonic SCs that contribute to CRC development [49, 50]. Moreover, HOXA9 is known to have a
pivotal role in HSC self-renewal and that the upregulation
of HOXA9 leads to AML [82]. Another report showed that
miR-375 inhibited the proliferation of CSCs and tamoxifen
resistance by targeting HOXB3 in human ER-positive
breast cancers [83].
2.3. HOX Genes as Biomarkers. HOX genes have been used
as markers to distinguish stromal populations from diﬀerent
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Figure 8: Correlation analysis of HOX genes and retinoid receptors with stem cell markers in colorectal cancer. (a) The expression of HOXA9
and ALDH1A1 (SC marker) in colorectal cancer (CRC) patients is correlated by Pearson correlation. A positive signiﬁcant correlation was
observed between HOXA9 and ALDH1A1 (r = 0 12, P = 0 048). (b) The expression of retinoid receptor RXRB and ALDH1A1 in CRC
patients is correlated by Pearson correlation. A negative signiﬁcant correlation was observed between RXRB and ALDH1A1 (r = −0 13,
P = 0 026). (c) The expression of HOXA4 and ALCAM (CD166, SC marker) in CRC patients correlated by Pearson correlation. A
negative signiﬁcant correlation was observed between HOXA4 and ALCAM (r = −0 14, P = 0 024). (d) The expression of HOXA9 and
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HOXA9

phenotypically similar. These stromal cell populations express
diﬀerent HOX genes and their level of expression varies.
Overall, these results indicate that HOX gene proﬁles can
be used to provide positional, embryological, and hierarchical identity of human stromal stem cells [84].
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myeloid leukemia (AML) using TCGA dataset. Survival analysis
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of 25th percentile. Credits: http://www.oncolnc.org.

tissue sources. The results show that the stromal populations
have distinct HOX signatures with diﬀerent growth and
diﬀerentiation abilities although they are all immuno-

3.1. Aberrant Self-Renewal and Proliferation. We have shown
that HOXA4 and HOXA9 are upregulated in CRC SCs [49,
50] and that siRNA knockdown of HOXA4 and HOXA9
reduces proliferation and sphere-formation ability of CRC
SCs. HOXA4 and HOXA9 knockdown also changed the
expression of SC markers, such as ALDH1, ALCAM,
(CD166) and LGR5. Treatment of CRC cells with the diﬀerentiating agent all-trans-retinoic acid (ATRA) decreased
HOXA4, HOXA9, and HOXD10 expression in parallel with
decreases in SC levels. Overall, our study demonstrated a role
for HOX genes in self-renewal and proliferation of CRC SCs.
Thus, strategies designed to modulate HOX expression may
provide a means to target malignant SCs and to develop more
eﬀective therapies for CRC [50].
Notably, the self-renewal ability of HOXB4 is dependent
upon a proline-rich sequence near the N terminus, which is
also unique and highly conserved among the other HOX proteins. Deletion of this domain signiﬁcantly enhanced the
oncogenicity of Hoxb4, promoting features of acute leukemia
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in mice. Insertion of this domain into Hoxa9 impaired oncogenic potential for leukemia. Overall, this study showed that
such proline-rich stretches in HOX genes attenuate the
potential of SCs to acquire oncogenic properties [85].

4. HOX Genes and Related Therapeutics
4.1. HOTAIR Long Noncoding RNA (lncRNA). HOTAIR is a
2.2 kilobase trans-acting lncRNA residing in the HOXC loci
that function to repress transcription of 40 kilobases of the
HOXD locus. HOTAIR has been shown to interact with
polycomb repressive complex 2 (PRC2). Its interaction with
PRC2 is required for PRC2 occupancy and histone H2
lysine-27 trimethylation of the HOXD locus [86]. HOTAIR
has been proposed as a biomarker in cervical cancer [87],
nasopharyngeal carcinoma [88], and gallbladder cancer
[89]. Indeed, meta-analysis involving 748 patients from 8
studies showed HOTAIR is a molecular marker for lymph
node metastasis. The results indicated a signiﬁcant diﬀerence
in the incidence of lymph node metastasis between high and
low HOTAIR expression groups [90]. HOTAIR lncRNA
plays a crucial role in epithelial-mesenchymal transitions
and is required for the maintenance of colon and breast
cancer stem cell stemness [91]. Overall, HOTAIR lncRNA
has potential as a therapeutic target in several cancer
types. A recent study showed that expression of HOTAIR
increased in CRC cells and cell lines and HOTAIR knockdown promoted apoptosis and inhibited proliferation, migration, and invasion in vitro and in vivo. Furthermore,
HOTAIR modulated CRC progression by competitively
binding miR-197 [92].
4.2. PBX/HOX Dimer. One of the mechanisms that regulates
HOX transcriptional expression is through binding with PBX
proteins. Both HOX and PBX proteins are known to play
critical roles in carcinogenesis, which makes it an attractive
therapeutic target for cancers. One study showed that PBX3
is a potential pathologic cofactor of HOXA9 involved in cytogenetically abnormal acute myeloid leukemia (CA-AML),
particularly MLL-rearranged AML. The depletion of PBX3
expression by shRNA signiﬁcantly inhibited MLL-fusionmediated cell transformation, whereas coexpression of
PBX3 with HOXA9 promoted cell transformation in vitro
and leukemogenesis in vivo. A small peptide, known as
HXR9, that disrupts the interaction between HOX and PBX
proteins was found to be eﬀective in killing leukemic cells
that were overexpressing HOX/PBX3 genes, which suggests
a potential therapeutic strategy for CA-AML patients [93].
HXR9 has anticancer eﬀects in other tumor types, such as
breast [94], mesothelioma [95], ovarian [96], meningioma
[97], prostate [98], and non-small cell lung [99]. Additionally, the disruption of HOXB7/PBX2 proteins by HXR9 is a
potential therapeutic target in malignant melanoma [100].
A recent study also showed that the expression of HOXA5,
HOXB2, HOXB4, HOXB9, and HOXC9 (but not HOXA9)
in primary AML cases is signiﬁcantly correlated with survival. HXR9 treatment is cytotoxic to AML-derived cell lines
and primary AML cells from patients. And it was shown that
cell death is independent of apoptosis. Rather, it involves
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necroptosis (a regulated form of necrosis) [101]. This study
suggests that HXR9 treatment for cancers should be seriously
explored in future studies. In addition to the upregulation of
HOXA4, HOXA9, and HOXD10 in CRC [49, 50, 58], the PBX
genes are also overexpressed in CRC, which correlates with
invasive potential in vitro and lymph node invasion, distant
metastasis, advanced TNM stage, and poor overall survival
of patients [102]. These reports suggest that HXR9 treatment
in CRCs might be therapeutically useful to target HOX/PBX
proteins in CRCs.

5. Conclusion
The above ﬁndings suggest that (i) HOX genes play diverse
roles in normal SC functions and properties, from selfrenewal to multilineage diﬀerentiation, and (ii) the dysregulation of HOX genes contributes to cancer development
through aberrant self-renewal and diﬀerentiation of SCs.
Thus, understanding the molecular mechanisms for how
HOX genes control SC self-renewal and diﬀerentiation will
ultimately help us understand how SC populations are maintained in normal, disease-free states and how the dysregulation of HOX genes leads to abnormal SC self-renewal and
diﬀerentiation that drive cancer development. Ultimately,
understanding the mechanisms by which HOX genes are regulated in SC might help to ﬁnd ways to manipulate SC fate
resulting in the development of novel, more eﬀective SCtargeted treatments for cancer.
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